Gamma-butyrobetaine hydroxylase 1 (BBOX1)

Gamma-butyrobetaine hydroxylase 1 (BBOX1) is a key enzyme in the biosynthesis of L-carnitine, catalyzing the hydroxylation of gamma-butyrobetaine to L-carnitine, which is vital for mitochondrial fatty acid transport and oxidation[1][3][4][5]. Carnitine biosynthesis is essential for energy metabolism, particularly in tissues with high oxidative demands such as muscle and heart. BBOX1 is classified in the 2-oxoglutarate-dependent dioxygenase superfamily and is highly expressed in the kidney, and to a lesser extent in liver and brain[3]. Disruption or mutation of BBOX1 leads to primary carnitine deficiency, manifesting clinically as hypoketotic hypoglycemia, muscle weakness, and cardiomyopathy[1][5]. Recent research has identified BBOX1 as a potential therapeutic target in cancer biology, with specific relevance to triple-negative breast cancer due to its role in supporting metabolic adaptation in tumor cells[7][9]. Drugs such as meldonium act by inhibiting BBOX1, resulting in decreased carnitine production[3]. Safety concerns for therapeutic targeting include the risk of systemic carnitine deficiency and disruption of energy metabolism[1][5].

Other names

Gamma-butyrobetaine dioxygenaseBBOXBBHG-BBHgamma-BBHgamma-butyrobetaine,2-oxoglutarate dioxygenasebutyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1gamma-butyrobetaine,2-oxoglutarate dioxygenase 1

Inhibition of carnitine biosynthesis (by inhibiting BBOX1, leading to lower L-carnitine and disrupting fatty acid transport and oxidation)[7][3]. Modulation of cellular energy metabolism, especially in cancer tissue dependent on fatty acid oxidation[7].